Reducing Treatment Doses in Head and Neck Cancer to Improve QOL
In this video we discuss efforts to reduce treatment doses in order to lessen long-term side effects and improve quality of life among patients with head and neck cancers.
In this video, Barbara Burtness, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses efforts to reduce treatment doses in order to lessen long-term side effects and improve quality of life (QOL) among patients with head and neck cancers.
One of the studies she discusses was recently published in the Journal of Clinical Oncology and showed that a subgroup of patients with human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma who were treated at a reduced radiation dose (≤ 54 Gy) had reduced side effects, with fewer patients having difficulty swallowing solid food (40% vs 89%; P = .011) or impaired nutrition (10% vs 44%; P = .025).
Pembrolizumab/Lenvatinib Combo Shows Mixed Results in Recurrent/Metastatic HNSCC
March 1st 2024Frontline pembrolizumab with or without chemotherapy appears to remain a standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma based on data from the LEAP-010 study.
